GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kolon Life Science Inc (XKRX:102940) » Definitions » EV-to-Revenue

Kolon Life Science (XKRX:102940) EV-to-Revenue : 2.66 (As of May. 25, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Kolon Life Science EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Kolon Life Science's enterprise value is ₩350,802 Mil. Kolon Life Science's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was ₩131,823 Mil. Therefore, Kolon Life Science's EV-to-Revenue for today is 2.66.

The historical rank and industry rank for Kolon Life Science's EV-to-Revenue or its related term are showing as below:

XKRX:102940' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.34   Med: 3.29   Max: 16.05
Current: 2.66

During the past 13 years, the highest EV-to-Revenue of Kolon Life Science was 16.05. The lowest was 1.34. And the median was 3.29.

XKRX:102940's EV-to-Revenue is ranked worse than
55.76% of 1024 companies
in the Drug Manufacturers industry
Industry Median: 2.285 vs XKRX:102940: 2.66

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-25), Kolon Life Science's stock price is ₩21950.00. Kolon Life Science's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was ₩10,669.52. Therefore, Kolon Life Science's PS Ratio for today is 2.06.


Kolon Life Science EV-to-Revenue Historical Data

The historical data trend for Kolon Life Science's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kolon Life Science EV-to-Revenue Chart

Kolon Life Science Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.77 3.04 3.23 2.35 3.16

Kolon Life Science Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.79 3.01 2.96 3.16 1.98

Competitive Comparison of Kolon Life Science's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Kolon Life Science's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kolon Life Science's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kolon Life Science's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Kolon Life Science's EV-to-Revenue falls into.



Kolon Life Science EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Kolon Life Science's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=350802.469/131823.499
=2.66

Kolon Life Science's current Enterprise Value is ₩350,802 Mil.
Kolon Life Science's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩131,823 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kolon Life Science  (XKRX:102940) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Kolon Life Science's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=21950.00/10669.523
=2.06

Kolon Life Science's share price for today is ₩21950.00.
Kolon Life Science's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩10,669.52.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kolon Life Science EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Kolon Life Science's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Kolon Life Science (XKRX:102940) Business Description

Traded in Other Exchanges
N/A
Address
110, Magokdong-ro, Gangseo-gu, One & Only Tower, Seoul, KOR
Kolon Life Science Inc develops, manufactures and sells Biopharmaceuticals, Active pharmaceutical ingredients, Antimicrobials and Water solutions. Its products include Invossa, KLS-1010, KLS-2020, Azilsartan, Besfloc etc. The company has manufacturing facilities in Chungju, Eumsung and Kimchun.

Kolon Life Science (XKRX:102940) Headlines

No Headlines